Results 131 to 140 of about 6,597 (237)

Abrocitinib Monotherapy for Refractory Prurigo Nodularis: Report of Two Successful Cases

Jingyao Liang,1,2,* Wei Li,1,2,* Wenyan Liu,1,2 Yihui Yu,1,2 Hui Ye,1,2 Xibao Zhang1,2 1Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, 510095, People’s Republic of China; 2Department of Dermatology, Guangzhou ...
Li W, Liang J, Zhang X, Ye H, Liu W, Yu Y   +5 more
core  

The State of the Art in Chronic Prurigo Nodularis. [PDF]

Dermatol Ther (Heidelb)
Serra-Baldrich E, Flórez Á, Julià Manresa M, Ortiz de Frutos FJ, Pereyra-Rodriguez JJ, Pérez B, Figueras I.   +6 more
europepmc   +1 more source

Clinical Outcomes of Abrocitinib in Prurigo Spectrum Disorders: A Case Series. [PDF]

Cureus
Chakravadhanula U, Nagarajan M, Bhat S.
europepmc   +1 more source

Itch: A Global Problem?

Frontiers in Medicine, 2021
Elke Weisshaar
doaj   +1 more source

Use of dupilumab in the management of refractory prurigo nodularis in an immunosuppressed double transplanted patient. [PDF]

An Bras Dermatol
Valenzuela Godoy D, Agüero R, Kolbach M.   +2 more
europepmc   +1 more source

Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel. [PDF]

Dermatol Ther (Heidelb)
Mendes-Bastos P, Lobo I, Pires da Rosa G, Pimenta R, Gonçalo M, Delphi panel.   +5 more
europepmc   +1 more source

Real-world Clinical Efficacy and Patient-reported Treatment Satisfaction of Nemolizumab Treatment in Prurigo Nodularis. [PDF]

Acta Derm Venereol
Mima Y, Yamamoto M, Iozumi K.
europepmc   +1 more source

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial. [PDF]

Dermatol Ther (Heidelb)
Wu C, Niu X, Wang X, Su J, Zhao H, Lin M, Yang C, Qin X, Guo S, Jiang C, Tang H, Yang H, Wu L, Zhu M, Wei A, Tao X, Zhang Y, Shu C, Liu J, Yang L, Qian Y, Zhang B, Zhang S, Xu J, Lu Y, Peng M, Luo S, Ma W, Jin H.   +28 more
europepmc   +1 more source

Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: A Post Hoc Analysis of Pooled Results from the PRIME and PRIME2 Trials. [PDF]

Dermatol Ther (Heidelb)
Stander S, Zeidler C, Msihid J, Makhija M, Bansal A, Wiggins S, Zahn J, Thomas RB, Bahloul D.   +8 more
europepmc   +1 more source

Issue Information

JEADV Clinical Practice, Volume 5, Issue 2, Page 351-356, June 2026.
wiley   +1 more source